By Christopher P. Singer --
In an April 26, 2007 press release SciClone Pharmaceuticals Inc. announced that it acquired exclusive rights in the U.S. and Canada to develop and commercialize a compound in the clinical stage for treatment of pancreatic cancer. The drug, RP101, was brought to Phase I clinical trials as a combination treatment with gemcitabine by Resistys, Inc., a wholly-owned subsidiary of Avantogen Oncology, Inc. In acquiring the rights to RP101 from Avantogen, SciClone expects to initiate a Phase II clinical study to assess the compound's effectiveness in treating late-stage pancreatic cancer by the end of 2007.
Under the terms of the agreement, SciClone receives exclusive development and commercialization rights in the U.S. and Canada, in exchange for payments to Resistys, including an upfront payment of about $1.7 million, a $1.3 million milestone payment upon initiation of the Phase II clinical study, post Phase III regulatory and commercial payments of up to $22 million, and royalty payments on future sales.
Dear friends!
My father have Pancreatic Cancer(caput).
Have a chance?
Posted by: Grigoriy Bogorad | September 21, 2007 at 04:10 AM